Summary
Antihistamines H1+H2 is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. No registered clinical trial in this database tests Antihistamines H1+H2 specifically in Long COVID. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 2 publications for this pair: 2 curated references. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | D · Anecdotal |
|---|---|
| Evidence score | 3.0 (trials 0.0, literature 3.0, tier 0, approved bonus 0.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 2 (2 curated references) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not specified |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Antihistamines H1+H2 to Long COVID in the current OSMF trial extract.
Published literature
- Curated reference (PACVS Evidence Map) 29% symptom-free at 20 days; fatigue, tachycardia, abdominal symptoms significantly lower in treated group; not statistically significant (underpowerePACVS Evidence Map
- Curated reference (PACVS Evidence Map) Gradual symptom improvement over 4–16 weeks; gradual response argues against placebo; T cell alterations documentedPACVS Evidence Map
Mechanism and notes
Recorded mechanism or class: Not specified.
Clinical notes: Investigational for listed conditions. 0 associated trial(s) and 2 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Antihistamines H1+H2 approved for Long COVID?
Antihistamines H1+H2 is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Antihistamines H1+H2 in clinical trials for Long COVID?
No registered clinical trial in this database tests Antihistamines H1+H2 specifically in Long COVID. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Antihistamines H1+H2 in Long COVID?
The record for Antihistamines H1+H2 in Long COVID rests on 2 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is D (Anecdotal), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.